FluBlok, a recombinant hemagglutinin influenza vaccine

Influenza Other Respir Viruses. 2008 Nov;2(6):211-9. doi: 10.1111/j.1750-2659.2008.00053.x.

Abstract

FluBlok, a recombinant trivalent hemagglutinin (HA) vaccine produced in insect cell culture using the baculovirus expression system, provides an attractive alternative to the current egg-based trivalent inactivated influenza vaccine (TIV) manufacturing process. FluBlok contains three times more HA than TIV and does not contain egg-protein or preservatives. This review discusses the four main clinical studies that were used to support licensure of FluBlok under the 'Accelerated Approval' mechanism in the United States.

Publication types

  • Multicenter Study
  • Randomized Controlled Trial
  • Review

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Animals
  • Double-Blind Method
  • Female
  • Humans
  • Influenza Vaccines / administration & dosage
  • Influenza Vaccines / adverse effects*
  • Influenza Vaccines / immunology*
  • Male
  • Middle Aged
  • Placebos / administration & dosage
  • United States
  • Vaccines, Synthetic / administration & dosage
  • Vaccines, Synthetic / adverse effects
  • Vaccines, Synthetic / immunology
  • Young Adult

Substances

  • FluBlok
  • Influenza Vaccines
  • Placebos
  • Vaccines, Synthetic